An illustration · invented records · this source is real
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Andre F, Ismaila N, Allison KH, Barlow WE, et al. (2022). Journal of Clinical Oncology. PubMed 35439025 · DOI 10.1200/JCO.22.00069 · PubMed record
What kind of source: Professional society guideline (American Society of Clinical Oncology). Where it sits in the summary: Established. Back to the summary
What it says, in plain language
The 2022 ASCO guideline on when genomic tests may be used to guide chemotherapy decisions. For postmenopausal women (or over 50) with ER-positive, HER2-negative disease and zero to three positive nodes, clinicians may use the 21-gene test among others. It also states what the tests cannot do.
Source access: this note uses the published abstract, linked above. The full article was not available for this review and is not included in the folder.
The exact words we relied on
“Clinicians may use Oncotype DX, MammaPrint, Breast Cancer Index (BCI), and EndoPredict to guide adjuvant endocrine and chemotherapy in patients who are postmenopausal or age > 50 years with early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative (ER+ and HER2-) breast cancer that is node-negative or with 1-3 positive nodes.” — PMID:35439025, Abstract, Recommendations
“Current data suggest that premenopausal patients with 1-3 positive nodes benefit from chemotherapy regardless of genomic assay result.” — PMID:35439025, Abstract, Recommendations
“There are no data on use of genomic tests to guide adjuvant chemotherapy in patients with ≥ 4 positive nodes.” — PMID:35439025, Abstract, Recommendations
“Treatment decisions should also consider disease stage, comorbidities, and patient preferences.” — PMID:35439025, Abstract, Recommendations
How these quotes were checked
Follow the passage links above to the included paper or public source record.
Abstract only. The quotes above come from the paper’s published abstract as held in the PubMed record. They were checked by exact string match against the PubMed record cached on 2026-09-08. This note is limited to the abstract; the full article was not read.
Limits of this source
A published erratum (PubMed 35896046, J Clin Oncol 2022;40(22):2514, read 2026-09-10) changes the evidence-quality label on Recommendation 1.3, which concerns women 50 or younger with scores 16 to 25, from high to intermediate. Nothing cited here rests on that recommendation. Abstract only; the full guideline is at www.asco.org/breast-cancer-guidelines.
Review
Reviewed by Sarah Kiselycznyk · September 10, 2026. Review scope and verification method: How we researched this.